2484949-51-9
2484949-51-9
Chemical Structure
Evorpacept
Synonym(s): ALX148
- CAS No.: 2484949-51-9
- Formula:N/A
- Molecular Weight:(76.61 kDa)
IUPAC Name: methyl 1-(piperidin-4-yl)-1H-1,2,3-triazole-4-carboxylate
SMILES: [Evorpacept]
Biological Activity: Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Evorpacept | 99.75% | Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kauder SE, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018;13(8):e0201832. Published 2018 Aug 22. [Content Brief]
- [2]. Guillermo Garcia-Manero, et al. Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02). blood. Volume 138, Supplement 1, 23 November 2021, Page 2601.
- [3]. Kim TM, et al. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica. 2025;110(9):2102-2112. [Content Brief]
- [4]. Guillermo Garcia-Manero, et al. Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part. Blood (2022) 140 (Supplement 1): 9046–9047.
Keywords
